Healthcare
Live Price
Offline$0.635
+0.63% today
1Y Change
-28.99%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VYNE Therapeutics Inc. (VYNE) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.63 and down 29.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +13.8%, EPS growth of +34.0%, a dividend yield of 0.0%. What stands out right now is revenue +13.8%, EPS +34.0%, free cash flow +2.8% with operating margin -5219.1% and ROIC -107.1%. Valuation already assumes a fairly strong business story at price/sales 19.2. Stock Foundry combines VYNE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYNE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VYNE Max Drawdown
-83.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VYNE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$931.0K
+95.2% YoY
FY Net Income
-$73.3M
-215.9% YoY
Free Cash Flow
-$56.4M
-93.0% YoY
Revenue Growth
+13.8%
EPS Growth
+34.0%
Gross Margin
99.1%
Net Margin
-4646.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 570K | 501K | 424K | 477K | 931K |
| Gross Profit | 547K | 501K | 424K | 477K | 931K |
| Operating Income | -30M | -44M | -29M | -34M | -39M |
| EBITDA | -27M | -44M | -29M | -34M | -39M |
| Net Income | -26M | -40M | -28M | -23M | -73M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 24M | 20M | 31M | 31M | 42M |
| Total Assets | 30M | 67M | 98M | 41M | 67M |
| Total Liabilities | 2M | 15M | 9M | 10M | 18M |
| Shareholder Equity | 28M | 52M | 89M | 31M | 49M |
| Total Debt | 0 | 99K | 214K | 0 | 349K |
| Net Debt | -24M | -20M | -30M | -31M | -42M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
56M
-93.0% YoY
Capital Expenditures
0
Free Cash Flow
56M
-93.0% YoY
Key ratios
Gross Margin
99.1%
Operating Margin
-5219.1%
Net Margin
-4646.1%
ROE
-74.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.